The sensitivity for DNA adduct formation by antitumor alkylating agent
s (mechlorethamine, cisplatin and adozelesin) of the postlabeling tech
nique and thin-layer chromatography was studied. Three DNAs were used:
a double-stranded 20-bp oligonucleotide of defined sequence, calf thy
mus DNA and murine leukemia L1210 cellular DNA. With high concentratio
ns of mechlorethamine, there was a marked decrease in normal dGp, a le
sser decrease in dAp and dCp and no change in dTp. Using 2D mapping PE
I-cellulose thin-layer chromatography analyses, it was found that six
mechlorethamine: DNA adducts were produced after a short exposure to m
echlorethamine. After an extended time at relatively high drug concent
rations there was an alteration in the mechlorethamine: DNA adduct pat
tern that may reflect the conversion of monoadducts to crosslinked add
ucts. Similar observations were made with cisplatin and adozelesin. Wh
en murine leukemia L1210 cells were treated with 50 mu M mechlorethami
ne or 50 mu M cisplatin for 1 h, six or more mechlorethamine: DNA addu
cts and fire cisplatin: DNA adducts were detected. After allowing 6 h.
for repair of potentially lethal damage, several adducts were no long
er detectable and others appeared with diminished intensity. Nuclease
P-1 dephosphorylates normal nucleotides at relatively low enzyme conce
ntrations with variation depending upon the nucleotide. In general, co
nsiderably lower concentrations of nuclease P-1 were required to depho
sphorylate the normal nucleotides than to dephosphorylate the antitumo
r alkylating agent: nucleotide adducts, thus allowing increased sensit
ivity of the postlabeling assay. The sensitivity of detection of antit
umor alkylating agent: DNA adducts in DNA from treated L1210 cells app
roached one adduct per 10(7)-10(8) nucleotides. These results suggest
that the postlabeling technique may be sufficiently sensitive and spec
ific for the study of the clinically effective levels of antitumor alk
ylating agents.